

Neoplasia I

Definitions, Terminology, and Morphology

Patrice Spitalnik, MD
pfs2101@columbia.edu

Cancer - second leading cause of
deaths in the US after CV disease

Nomenclature

- Neoplasia “new growth”
- Neoplasms arise from genetic changes that allow excessive, unregulated cell proliferation
- Cell type of parenchyma + OMA

Tissue Type	Cell Type	Benign	Malignant
Conn. Tissue	Fibroblast	Fibroma	Fibrosarcoma
	Adipocyte	Lipoma	Liposarcoma
	Cartilage	Chondroma	Chondrosarcoma
	Bone	Osteoma	Osteosarcoma
Vessels, etc	Endothelial cells	Hemangioma	Angiosarcoma
	Meninges	Meningioma	Invasive meningioma
Muscle	Smooth muscle	Leiomyoma	Leiomyosarcoma
	Skeletal muscle	Rhabdomyoma	Rhabdomyosarcoma
Epithelium	Stratified Squamous	Squamous papilloma	Squamous cell carcinoma
	Ducts or glands	Adenoma	Adenocarcinoma
Melanocytes	Melanocytes	Nevus	Melanoma

Characteristics of Benign & Malignant Neoplasms

- Tissue Architecture – histologic features
- Cytologic features
- Terminology
 - Differentiation/anaplasia
 - Dysplasia
 - Rate of growth
 - Local Invasion
 - Metastasis

Characteristics of Benign & Malignant Neoplasms


- **Tissue architecture**
 - **Benign** - well circumscribed, usually encapsulated
 - **Malignant** – poorly circumscribed, lack of cell polarity and epithelial cell connections

Characteristics, con't.

- **Cytologic features**
 - **Benign** – small, uniform cells, no visible nucleoli
 - **Malignant** – large, pleomorphic cells with large hyperchromatic nuclei, N:C ratio 1:1 (nl. 1:4), large nucleoli, irregular nuclear outlines

Differentiation



- Refers to original parenchymal cell, tissue appearance and function
 - **Benign** - well differentiated, resembles cell of origin with few mitoses, secretion of products, hormones, mucins, etc.
 - **Malignant** - well to poorly differentiated with numerous, bizarre mitoses



Abnormal mitosis


Anaplasia

- Neoplasm without apparent differentiation, undifferentiated cells



Dysplasia

- Disorderly cellular maturation
- If, full epithelial involvement –carcinoma in situ, pre-invasive stage
- HPV – cervix
- Smoking- respiratory tract
- GERD – esophagus



Rate of Growth


- Benign – slower growth, some dependent on hormones, leiomyoma
- Malignant – more rapid growth, areas of necrosis


Local Invasion

- Benign – most encapsulated and cannot invade or spread to other sites
- Malignant – not encapsulated and can invade

Benign Neoplasia

- Remains localized
- Cannot spread to other sites
- Most patients survive, but some tumor locations can cause serious problems (brain stem, spinal cord, pituitary)










Malignant Neoplasia

- Can invade and destroy adjacent tissue
- Can spread to distant sites, metastasis













Metastasis

- Dissemination to other organs:
 - Seeding of body cavities (ovary)
 - Lymphatic spread (carcinoma)
 - Hematogenous dissemination (sarcoma)


Steps of Successful Metastasis

- **Detachment of tumor cells** (E-cadherin loss)
- **Degradation of ECM** (MMP's - overexpressed and TIMP's - reduced)
- **Attachment to new ECM proteins** (cleavage products of collagen and laminin bind to receptors on tumor cells - stimulate migration)
- **Migration of tumor cells** (cytokines from tumor cells direct movement, autocrine, and stromal cells produce paracrine effectors, HGF/SCF, for motility that bind to tumor cells)








Homing of Tumor Cells





Homing of Tumor Cells

- Most metastases predicted by vascular and lymphatic drainage
- Some homing related to expression of endothelial adhesion molecules
- **Chemokines and chemokine receptors** are also involved in homing. (breast ca cells-chemokine receptors: CXCR-4 and -7 bind to the chemokines CXCL12 and CCL21 on distant organs)
- After extravasation, tumor cells survive only in receptive ECM and stroma







Cinical Aspects of Neoplasia

1. Epidemiology:

Cancer incidence—Cancer deaths


2. Pathogenetic factors: a balance of risks



3. Clinical effects of cancer

4. Death in cancer

5. Grading and Staging

6. Diagnosis









Table 6-3 Inherited Predisposition to Cancer

Inherited Cancer Syndromes (Autosomal Dominant)	
Gene	Inherited Predisposition
<i>RB</i>	Retinoblastoma
<i>p53</i>	Li-Fraumeni syndrome (various tumors)
<i>p16INK4A</i>	Melanoma
<i>APC</i>	Familial adenomatous polyposis/colon cancer
<i>NF1, NF2</i>	Neurofibromatosis 1 and 2
<i>BRCA1, BRCA2</i>	Breast and ovarian tumors
<i>MEN1, RET</i>	Multiple endocrine neoplasia 1 and 2
<i>MSH2, MLH1, MSH6</i>	Hereditary nonpolyposis colon cancer
<i>PATCH</i>	Nevoid basal cell carcinoma syndrome


Familial Cancers

Familial clustering of cases, but role of inherited predisposition not clear for each individual

- Breast cancer (not linked to BRCA1 or BRCA2)
- Ovarian cancer
- Pancreatic cancer

Inherited Autosomal Recessive Syndromes of Defective DNA Repair

- Xeroderma pigmentosum
- Ataxia-telangiectasia
- Bloom syndrome
- Fanconi anemia



Clinical Effects of Cancer

- Cachexia**
-cytokines → anorexia
TNF: from macrophages/tumor cells
-suppresses appetite
-inhibits lipoprotein lipase (inhibits FFA release from lipoprot's)
Proteolysis-inducing factor:
-breaks down skeletal muscle
- Paraneoplastic syndromes**
-hormone production by tumor cells
-present in 10% - 15% of pts. with cancer
- Venous thrombosis**
-mucins from Ca's activate clotting
e.g. Pancreas: Trousseau phenomenon

Small cell Ca
-ACTH or ACTH-like subst. → Cushing syndrome
-ADH → SIADH

Squamous cell Ca
→ PTH-related prot. → hypercalcemia

Death in Cancer

1. Overwhelm organ function

- liver: ↓ coagulation, other protein synthesis
- lung: ↓ diffusion/oxygenation
- pancreas: biliary obstruction/liver mets → anorexia

2. Pulmonary embolus (pro-thrombotic Ca's)

3. Progressive somnolence: hypercalcemia, etc.

4. Systemic electrolyte imbalances:

- cardiac arrhythmia
- ↓ mentation

5. Tumor-related products:

- depression/other CNS effects



Diagnosis of Cancer

- History—physical—occupation—exposure
- Radiology
- Blood tests: tumor markers
- Morphologic Diagnosis
 - light microscopy: biopsy
 - cytology (Fine Needle Aspiration—FNA)
 - immunohistochemistry
 - fluorescence *in situ* hybridization (FISH)
 - molecular probes, incl. gene microarray
 - flow cytometry (lymphomas, leukemias)

Tumor Markers

*Molecules in plasma produced by tumor cells

Oncofetal antigens



carcinoembryonic antigen (CEA)

colon Ca; pancreas, lung, breast Ca

alphafetoprotein (AFP)

hepatocellular Ca, germ cell testis Ca

Specific proteins



PSA (prostatic specific antigen)

Mucins & other glycoproteins: CA's: carbohydrate antigens



CA-125
ovary



CA-19-9
bile ducts, panc.



CA-15-3
breast

Hormones
trophoblastic tumor (placenta)



HCG




medullary Ca thyroid


calcitonin

Immunohistochemistry:


--monoclonal Ab to specific cell Ag's





CK7+
CK20-



CK7-
CK20-



CK7-
CK20+



Cytokeratins in epith. cells:
CK7 and CK20







Table 2. Frequency of high epidermal growth factor receptor (EGFR) expression in lung cancer by histologic characterization


Histology	EGFR expression, % (n)
Small cell	0 (19)
Adenocarcinoma	65 (563)
Large cell	68 (72)
Squamous	84 (754)

Reprinted from Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. *Semin Oncol* 2002;29(suppl 14):38–44, with permission from Elsevier.





Staging: TNM AJC (American Joint Committee)



STAGE GROUPING			
AJC			
Stage 0	Tis	N0	M0
Stage IA	T1	N0	M0
Stage IB	T2	N0	M0
Stage IIA	T3	N0	M0
Stage IIB	T1	N1	M0
	T2	N1	M0
	T3	N1	M0
Stage III	T4	Any N	M0
Stage IV	Any T	Any N	M1

DEFINITION OF TNM

Primary Tumor (T)

- TX Primary tumor cannot be assessed
- T0 No evidence of primary tumor
- Tis Carcinoma *in situ**
- T1 Tumor limited to the pancreas, 2 cm or less in greatest dimension
- T2 Tumor limited to the pancreas, more than 2 cm in greatest dimension
- T3 Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery
- T4 Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor)

Regional Lymph Nodes (N)

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Regional lymph node metastasis

Distant Metastasis (M)

- MX Distant metastasis cannot be assessed
- M0 No distant metastasis
- M1 Distant metastasis